Literature DB >> 18558370

Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.

Frauke Neff1, Xing Wei, Carmen Nölker, Michael Bacher, Yansheng Du, Richard Dodel.   

Abstract

Parkinson's disease, Alzheimer's disease and other neurodegenerative disorders share a common pathologic pathway with aggregation and deposition of misfolded proteins causing a disruption of particular neuronal networks. Several mechanisms have been implicated in the down-stream events following deposition of misfolded proteins including failure of cellular defenses among many others. Recently, naturally occurring autoantibodies against ss-amyloid and alpha-synuclein have been detected in healthy persons and altered levels in patients were associated with particular neurodegenerative disorders. In this review the current knowledge on the role of naturally occurring autoantibodies is discussed in respect to neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558370     DOI: 10.1016/j.autrev.2008.04.010

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  21 in total

1.  [Innovative treatment approaches for Alzheimer's disease. Immunotherapy].

Authors:  R Dodel; M Bacher
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

Review 2.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 3.  α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.

Authors:  Michael X Henderson; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neurosci Lett       Date:  2019-06-03       Impact factor: 3.046

Review 4.  Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?

Authors:  Yvette C Wong; Kelvin Luk; Kerry Purtell; Samuel Burke Nanni; A Jon Stoessl; Louis-Eric Trudeau; Zhenyu Yue; Dimitri Krainc; Wolfgang Oertel; Jose A Obeso; Laura A Volpicelli-Daley
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

Review 5.  APP transgenic mice: their use and limitations.

Authors:  Claudia Balducci; Gianluigi Forloni
Journal:  Neuromolecular Med       Date:  2010-12-09       Impact factor: 3.843

6.  Involvement of the Fc gamma receptor in a chronic N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of dopaminergic loss.

Authors:  Arman Lira; Jerzy Kulczycki; Ruth Slack; Hymie Anisman; David S Park
Journal:  J Biol Chem       Date:  2011-06-21       Impact factor: 5.157

7.  The role of choroid plexus in IVIG-induced beta-amyloid clearance.

Authors:  Huiying Gu; Zhaohui Zhong; Wendy Jiang; Eileen Du; Richard Dodel; Martin R Farlow; Wei Zheng; Yansheng Du
Journal:  Neuroscience       Date:  2014-04-16       Impact factor: 3.590

Review 8.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

Review 9.  Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

Authors:  Gregory A Jicha
Journal:  Expert Opin Biol Ther       Date:  2009-04       Impact factor: 4.388

Review 10.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.